Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 12, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 13, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001225208-26-001893
Filed / recorded
Feb 13, 2026, 10:37 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
Edwards Lifesciences Corp
Issuer CIK
1099800
Ticker
EW
Reporting person
Bernard J Zovighian
Relationship
Director, Officer
Officer title
CEO
Security
Employee Stock Option (Right to Acquire)
Table
Derivative (Table II)
Transaction date
Feb 12, 2026
Transaction code
M
Shares / units
25,350
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.